Saalfeld et al. retrospectively evaluated outcomes of HER2-mutant NSCLC patients who were treated with immunotherapy or chemoimmunotherapy in the first-line setting (n = 27) or with ICIs in monotherapy as second or subsequent lines (n = 34). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.